Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Source: Senate LDA
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
China IP; US-Japan trade and reforms; KORUS; Korea reform; Taiwan reform; HR 252; Veterinary medicine trade matters; Brazil WTO Cotton case; Special 301
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Patent legislation; HR 1548; Follow-On Biologics; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP; Turkey pricing
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Japan bilateral trade architecture; reimbursement and regulatory reform, China IP; Korea FTA reimbursement & pricing reform; Taiwan TIFA and reimbursement & pricing reform; Indonesia investment decree; Philippines pricing reform; Thailand healthcare system reform; Agriculture (HR 2997, S 1406); Rural development; Food and Drug Administration Appropriations Act for 2010; China meat & poultry issues; Russia meat & poultry issues; UK meat & poultry issues; CODEX Alimentarius; Turkey pricing; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
America's Healthy Future Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Title I Education Funding Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual Property (IP) issues related to China, ASEAN countries, and India; IPR and Ambassadorial nominations for the UN; S. 242; Canada IP; Mexico IP; Brazil IP; Algeria IP; Egypt IP; Saudi Arabia IP; Peru IP/FTA implementation; Ecuador IP; Argentina IP; Chili IP; Columbia IP; Russia IP/WTO Accession; Turkey IP; Finland IP; Norway IP; Slovenia IP; Sweden IP
Title I Education Funding Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Title I Education Funding Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting; Anti-counterfeiting Trade Agreement (ACTA); Ambassadorial nominations for the UN, US_ASEAN Summit; Canada S. 242 and intellectual property (IP); Mexico IP; Peru FTA; Columbia FTA; Algeria access; UK pricing; Germany HC reform; Saudi Arabia access/IP; Cuba sanctions; Argentina access and IP; Poland WTO; Russia WTO; Turkey access; Brazil trade negotiations; Japan pricing and regulatory reform; China IPR; Korea pricing reform and FTA; Taiwan pricing reform; Agriculture Appropriations/Trade Provisions (HR 2997)
Physician Payments Sunshine Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
A bill to provide additional personnel authorities for the Special Inspector General for Afghanistan Reconstruction.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Anti-counterfeiting; Anti-counterfeiting Trade Agreement (ACTA); Ambassadorial nominations for the UN, US_ASEAN Summit; Canada S. 242 and intellectual property (IP); Mexico IP; Peru FTA; Columbia FTA; Algeria access; UK pricing; Germany HC reform; Saudi Arabia access/IP; Cuba sanctions; Argentina access and IP; Poland WTO; Russia WTO; Turkey access; Brazil trade negotiations; Japan pricing and regulatory reform; China IPR; Korea pricing reform and FTA; Taiwan pricing reform; Agriculture Appropriations/Trade Provisions (HR 2997)
Japan bilateral trade architecture; reimbursement and regulatory reform, China IP; Korea FTA reimbursement & pricing reform; Taiwan TIFA and reimbursement & pricing reform; Indonesia investment decree; Philippines pricing reform; Thailand healthcare system reform; Agriculture (HR 2997, S 1406); Rural development; Food and Drug Administration Appropriations Act for 2010; China meat & poultry issues; Russia meat & poultry issues; UK meat & poultry issues; CODEX Alimentarius; Turkey pricing; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Veterinary Medicine Market Access; Czech Republic (market access & pricing reform); European Union (Pharmaceutical Package legislation); Finland (IP); Germany (pricing & health care reform); Italy (pricing & health care reform); Norway (IP & market access); Poland (market access); Slovakia (IP & market access); Sweden (pricing & health care reform); United Kingdon (pricing & health care reform); Anti-Counterfeiting Trade Agreement; Latin America Free Trade Agreements; (CONTINUED ON NEXT PAGE) Canada (Pharmaceutical Market Access and Drug Safety Act - S 242 & access restrictions & IP); Cuba (omnibus bill & sanctions); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & access restrictions); Tunisia (IP & access restrictions); Egypt (IP); Saudia Arabia (IP & access restrictions); Peru (FTA Implementation); Argentina (IP & access restrictions); Chili (IP); Turkey (IP & access restrictions); Russia (IP & WTO accession); Israel (IP); Columbia (IP); South Africa (access restrictions); Japan (pricing & regulatory reform); China (anti-counterfeiting & pricing reform); Taiwan (pricing reform & IP); Korea (pricing reform); Thailand (CL); Indonesia (investment decree); Philippines (pricing reform);
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Affordable Biologics for Consumers Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Affordable Biologics for Consumers Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Affordable Biologics for Consumers Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Biologics Price Competition and Innovation Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Finland (IP), Belgium (pricing), Czech republic (market access & pricing reform), Finland (IP), Germany (pricing), Italy (pricing), Norway (market access), Poland (market access), Switzerland (parallel trade), United Kingdom (pricing), Korea Free Trade Agreement, Japan (pricing), China (pricing & regulatory), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price), Latin America Free Trade, Canada (S 242), Canada (access), Mexico (access), Brazil (access), Algeria & Tunisia (access), Saudia Arabia (access), Argentina (access)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242), Norway (market access), China (pricing)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242), Norway (market access), China (pricing)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242), Norway (market access), China (pricing)
Pharmaceutical Market Access and Drug Safety Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242)
Intellectual Property Rights Enforcement Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Intellectual Property Rights Enforcement Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
Intellectual Property Rights Enforcement Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
Intellectual Property Rights Enforcement Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Intellectual Property Rights Enforcement Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · first_quarter · Q1
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · Q4
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · first_quarter · Q1
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · 2A
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · fourth_quarter · Q4
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · first_quarter · 1A
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession; Saudi Arabia
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · 3A
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · Q4
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · 3A
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · second_quarter · Q2
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · fourth_quarter · Q4
Patent protection; Drug shortages; Drug Pricing and Value; Dormant Therapies Act; PPACA; 21st Century Cures; Innovations for Healthier Americans
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · third_quarter · Q3
Patent protection; Drug shortages; Drug Pricing and Value; Dormant Therapies Act; PPACA; 21st Century Cures; Innovations for Healthier Americans
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · first_quarter · Q1
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · fourth_quarter · Q4
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · third_quarter · Q3
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · second_quarter · Q2
Sanitary and Phytosanitary issues (SPS); TPP, Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · first_quarter · Q1
SPS Issues; Veterinary Medicine; TPP; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany Pricing Reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · fourth_quarter · Q4
TPP; Russia PNTR; Turkey Pricing; Veterinary Medicine - S/PS Issues; IPR and Pricing; Germany pricing reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · third_quarter · Q3
Trans-Pacific Partnership Agreement; Korean Free trade Agreement; TPP IP/Market Access; ASEAN Countries Market Access/IP; IMF Policy on Greece; Veterinary medicine - domestic and international trade; Germany pricing reforms; Poland market access; Greece pricing reform; Romania cost-containment; CEE cost-containment; Anti-Counterfeiting; Turkey policy; PNTR for Russia; Veterinary Medicine
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · second_quarter · Q2
Trans-Pacific Partnership Agreement; Korean Free trade Agreement; TPP IP/Market Access; ASEAN Countries Market Access/IP; IMF Policy on Greece; Veterinary medicine - domestic and international trade; Germany pricing reforms; Poland market access; Greece pricing reform; Romania cost-containment; CEE cost-containment; Anti-Counterfeiting; Turkey policy; PNTR for Russia
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · first_quarter · Q1
TPP IP/Market Access, ASEAN Countries Market Access/IP, Russia PNTR/Data Exclusivity, Veterinary Medicine - S/PS Issues, Germany Pricing Reforms, Poland Market Access, Greece Pricing Reform, Romania Market Access, Spain IP/Pricing, Turkey GMP Issue
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · fourth_quarter · Q4
Russia DE; Saudi Zyprexa Issue; Mexico IP legislation; Trade issues (S/PS, EU, China, Russia, Korea, Vietnam); IP Issues; China IPR, US-Japan Trade Forum and Reform; KORUS and Krean Reform; Taiwan Reforms; Turkey GMP Inspection Requirement; Germany Pricing Reform; Poland Market Access; Greece Pricing Reform; Italy Market Access; Veterinary Medicine - S/PS Issues
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · third_quarter · Q3
Russia DE; Saudi Zyprexa Issue; Mexico IP legislation; Trade issues (S/PS, EU, China, Russia, Korea, Vietnam); IP issues; China IPR; US-Japan trade forum and reform; KORUS and Korean reform; Taiwan reforms; Turkey GMP inspection requirement; Germany pricing reform, Poland market access, Greece pricing reform, Italy market access
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · second_quarter · Q2
China IPR; US-Japan trade forum and reform; KORUS and Korean reforms; Taiwan reforms; Turkey GMP inspection requirement; Veterinary medicine / CODEX; Germany pricing reforms; Poland market access; Greece pricing reform; Italy market access
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · first_quarter · Q1
China IP; US-Japan trade and reforms; KORUS; Korea reform; Taiwan reform; HR 252; Veterinary medicine trade matters; Brazil WTO Cotton case; Special 301
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · fourth_quarter · Q4
Intellectual Property (IP) issues related to China, ASEAN countries, and India; IPR and Ambassadorial nominations for the UN; S. 242; Canada IP; Mexico IP; Brazil IP; Algeria IP; Egypt IP; Saudi Arabia IP; Peru IP/FTA implementation; Ecuador IP; Argentina IP; Chili IP; Columbia IP; Russia IP/WTO Accession; Turkey IP; Finland IP; Norway IP; Slovenia IP; Sweden IP
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · third_quarter · Q3
Patent legislation; HR 1548; Follow-On Biologics; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP; Turkey pricing
Japan bilateral trade architecture; reimbursement and regulatory reform, China IP; Korea FTA reimbursement & pricing reform; Taiwan TIFA and reimbursement & pricing reform; Indonesia investment decree; Philippines pricing reform; Thailand healthcare system reform; Agriculture (HR 2997, S 1406); Rural development; Food and Drug Administration Appropriations Act for 2010; China meat & poultry issues; Russia meat & poultry issues; UK meat & poultry issues; CODEX Alimentarius; Turkey pricing; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · second_quarter · Q2
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Veterinary Medicine Market Access; Czech Republic (market access & pricing reform); European Union (Pharmaceutical Package legislation); Finland (IP); Germany (pricing & health care reform); Italy (pricing & health care reform); Norway (IP & market access); Poland (market access); Slovakia (IP & market access); Sweden (pricing & health care reform); United Kingdon (pricing & health care reform); Anti-Counterfeiting Trade Agreement; Latin America Free Trade Agreements; (CONTINUED ON NEXT PAGE) Canada (Pharmaceutical Market Access and Drug Safety Act - S 242 & access restrictions & IP); Cuba (omnibus bill & sanctions); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & access restrictions); Tunisia (IP & access restrictions); Egypt (IP); Saudia Arabia (IP & access restrictions); Peru (FTA Implementation); Argentina (IP & access restrictions); Chili (IP); Turkey (IP & access restrictions); Russia (IP & WTO accession); Israel (IP); Columbia (IP); South Africa (access restrictions); Japan (pricing & regulatory reform); China (anti-counterfeiting & pricing reform); Taiwan (pricing reform & IP); Korea (pricing reform); Thailand (CL); Indonesia (investment decree); Philippines (pricing reform);
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · 2A
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242), Norway (market access), China (pricing)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242), Norway (market access), China (pricing)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · 1A
United Kingdom (pricing reform), Italy (pricing & healthcare reform), Germany (pricing & healthcare reform), France (pricing & healthcare reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philppines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · fourth_quarter · Q4
EU Duties; Market Access (China, Germany, Czech Republic, Italy, Norway, Poland, United Kingdom, Indonesia); Intellectual Property (Finland, Norway, China, Philippines); Pricing Reform (Czech Republic, Japan, Korea, Thailand)
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · third_quarter · Q3
Finland (IP), Belgium (pricing), Czech republic (market access & pricing reform), Finland (IP), Germany (pricing), Italy (pricing), Norway (market access), Poland (market access), Switzerland (parallel trade), United Kingdom (pricing), Korea Free Trade Agreement, Japan (pricing), China (pricing & regulatory), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price), Latin America Free Trade, Canada (S 242), Canada (access), Mexico (access), Brazil (access), Algeria & Tunisia (access), Saudia Arabia (access), Argentina (access)
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242), Norway (market access), China (pricing)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · Q1
United Kingdom (pricing reform), Italy (pricing and health care reform), Germany (pricing and health care reform), France (pricing and health care reform), Poland (market access & IP), Russia WTO accession (market access), European Union (market access), Spain (IP), Japan (pricing & regulatory reform), Korea FTA (pricing, regulatory & IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (price control), Turkey (transparency & market access), Algeria (transparency), Latin America Free Trade Agreements, Canada (market access -- S 242)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
Anti-counterfeiting; Anti-counterfeiting Trade Agreement (ACTA); Ambassadorial nominations for the UN, US_ASEAN Summit; Canada S. 242 and intellectual property (IP); Mexico IP; Peru FTA; Columbia FTA; Algeria access; UK pricing; Germany HC reform; Saudi Arabia access/IP; Cuba sanctions; Argentina access and IP; Poland WTO; Russia WTO; Turkey access; Brazil trade negotiations; Japan pricing and regulatory reform; China IPR; Korea pricing reform and FTA; Taiwan pricing reform; Agriculture Appropriations/Trade Provisions (HR 2997)
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)